Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis

Abstract

The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and / or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application claims priority from International Application No. PCT / US2015 / 028336, filed on Apr. 29, 2015, which claims priority to U.S. application Ser. No. 61 / 986,719, filed on Apr. 30, 2014, which are hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present disclosure relates to methods for the treatment of sarcoidosis.BACKGROUND OF THE INVENTION[0003]PCT patent application publication WO 2007 / 004072 discloses methods of treating AA amyloidosis by administering 1,3 propanedisulfonic acid. PCT patent application publication WO 2007 / 0238788 discloses methods of treating diabetic neuropathy by administering 1,3 propanedisulfonic acid.[0004]Sarcoidosis is a rare condition that causes small patches of red and swollen tissue, called granulomas that can develop in multiple organs in the body, but mostly the lungs and skin. Corticosteroids, the mainstay of therapy in sarcoidosis, nonspecifically suppress ...

AI Technical Summary

Benefits of technology

The present patent provides methods for treating sarcoidosis by administering 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof to a subject. The treatment can involve administering the 1,3-propanedisulfonic acid or salt thereof to the subject at least once daily, with a dose ranging from 400 mg to 2000 mg per day. The treatment can also involve administering the 1,3-propanedisulfonic acid or salt thereof through various routes such as oral, injection, nasal, or transdermal delivery. The patent also provides pharmaceutical compositions comprising 1,3-propanedisulfonic acid or a salt thereof and a pharmaceutically acceptable carrier. These compositions may also contain a second agent, such as a corticosteroid, for the treatment of sarcoidosis. The technical effects of the patent include reducing inflammation and alleviating symptoms of sarcoidosis in the subject.

Problems solved by technology

Corticosteroids, the mainstay of therapy in sarcoidosis, nonspecifically suppress chronic granulomatous inflammation, often causing debilitating adverse effects but do not correct the underlying disease.

Images